A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

B7441007 is a randomized, double-blind, placebo-controlled, sponsor open, parallel group
design, Phase 1b study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of
3 doses of PF-06412562 (3 mg BID, 9 mg BID and 45 mg BID) over 15 days in approximately 100
psychiatrically stable (as defined by the inclusion and exclusion criteria) subjects with
schizophrenia are on background treatment with SOC antipsychotics and other psychotropic
medications.

All doses will be administered twice daily, with approximately 12 hours between each dose.

Inclusion Criteria:

1. Subjects with schizophrenia both male and female

2. Evidence of stable schizophrenia symptomatology for at least 3 months (no
hospitalizations for schizophrenia, no increase in level of psychiatric care due to
worsening of symptoms of schizophrenia, etc).

3. Subjects must be in ongoing maintenance antipsychotic therapy other than clozapine
(oral or depot) on a stable medication treatment regimen for for at least 2 months
prior to Day 1, including concomitant psychotropic medications.

Exclusion Criteria:

1. History of seizure

2. Pregnant or nursing females

3. Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic, or allergic disease
(including drug allergies, but excluding untreated, asymptomatic, seasonal allergies
at time of screening and at the time of dosing).